Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

505 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early prediction of lenvatinib treatment efficacy by using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observational study.
Takeuchi S, Shiga T, Hirata K, Taguchi J, Magota K, Ariga S, Gouda T, Ohhara Y, Homma R, Shimizu Y, Kinoshita I, Tsuji Y, Homma A, Iijima H, Tamaki N, Dosaka-Akita H. Takeuchi S, et al. Among authors: homma r, homma a. BMJ Open. 2018 Aug 30;8(8):e021001. doi: 10.1136/bmjopen-2017-021001. BMJ Open. 2018. PMID: 30166292 Free PMC article.
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
Mizumachi T, Homma A, Kakizaki T, Sakashita T, Kano S, Hatakeyama H, Tsuchiya K, Yasuda K, Onimaru R, Shirato H, Taguchi J, Shimizu Y, Kinoshita I, Akita H, Fukuda S. Mizumachi T, et al. Among authors: homma a. Int J Clin Oncol. 2015 Jun;20(3):431-7. doi: 10.1007/s10147-014-0726-y. Epub 2014 Jul 5. Int J Clin Oncol. 2015. PMID: 24993675 Free article.
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
Tahara M, Kiyota N, Yokota T, Hasegawa Y, Muro K, Takahashi S, Onoe T, Homma A, Taguchi J, Suzuki M, Minato K, Yane K, Ueda S, Hara H, Saijo K, Yamanaka T. Tahara M, et al. Among authors: homma a. Ann Oncol. 2018 Apr 1;29(4):1004-1009. doi: 10.1093/annonc/mdy040. Ann Oncol. 2018. PMID: 29408977 Free article. Clinical Trial.
Integrating quantitative morphological and intratumoural textural characteristics in FDG-PET for the prediction of prognosis in pharynx squamous cell carcinoma patients.
Fujima N, Hirata K, Shiga T, Li R, Yasuda K, Onimaru R, Tsuchiya K, Kano S, Mizumachi T, Homma A, Kudo K, Shirato H. Fujima N, et al. Among authors: homma a. Clin Radiol. 2018 Dec;73(12):1059.e1-1059.e8. doi: 10.1016/j.crad.2018.08.011. Epub 2018 Sep 21. Clin Radiol. 2018. PMID: 30245069 Free article.
Semi-quantitative analysis of pre-treatment morphological and intratumoral characteristics using 18F-fluorodeoxyglucose positron-emission tomography as predictors of treatment outcome in nasal and paranasal squamous cell carcinoma.
Fujima N, Hirata K, Shiga T, Yasuda K, Onimaru R, Tsuchiya K, Kano S, Mizumachi T, Homma A, Kudo K, Shirato H. Fujima N, et al. Among authors: homma a. Quant Imaging Med Surg. 2018 Sep;8(8):788-795. doi: 10.21037/qims.2018.09.09. Quant Imaging Med Surg. 2018. PMID: 30306059 Free PMC article.
A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Enokida T, Ogawa T, Homma A, Okami K, Minami S, Nakanome A, Shimizu Y, Maki D, Ueda Y, Fujisawa T, Motegi A, Ohkoshi A, Taguchi J, Ebisumoto K, Nomura S, Okano S, Tahara M. Enokida T, et al. Among authors: homma a. Cancer Med. 2020 Mar;9(5):1671-1682. doi: 10.1002/cam4.2852. Epub 2020 Jan 13. Cancer Med. 2020. PMID: 31943834 Free PMC article. Clinical Trial.
Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
Kitagataya T, Suda G, Nagashima K, Katsurada T, Yamamoto K, Kimura M, Maehara O, Yamada R, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Komatsu Y, Hata H, Takeuchi S, Abe T, Sakakibara-Konishi J, Teshima T, Homma A, Sakamoto N. Kitagataya T, et al. Among authors: homma a. J Gastroenterol Hepatol. 2020 Oct;35(10):1782-1788. doi: 10.1111/jgh.15041. Epub 2020 Mar 31. J Gastroenterol Hepatol. 2020. PMID: 32187734 Free article.
505 results